Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(12):874-876; doi:10.1093/jnci/97.12.874
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Garber, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garber, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

Divide and Conquer: New Generation of Drugs Targets Mitosis

Ken Garber

The first 150 words of the full text of this article appear below.

Interfering with mitosis is not a new way to treat cancer. More than a quarter century has passed since Randall Johnson, Ph.D., then at the National Cancer Institute, first showed that Taxol (paclitaxel) works against cancer by poisoning mitosis. Paclitaxel, and the even older vinca alkaloids, function by binding to microtubules, hollow structures that form the mitotic spindle, thus halting cell division. (Tumor cells then die by an unknown mechanism.) For decades, the microtubule was the only mitotic target.

But mitosis, the partitioning of a duplicated genome into two daughter cells, is a complex cellular drama with many actors. The microtubule is merely one. In the last few years, new mitotic targets have emerged in cancer, and inhibitors are moving with remarkable speed into the clinic.

Sidetracking Cell Division

One such target is a protein called KSP, for kinesin spindle protein. In 1985, Ronald Vale, Ph.D., at the Marine Biological Laboratory in Woods . . . [Full Text of this Article]

Window of Vulnerability?

Selection of Mitosis-Targeting Drugs in Development

Kinase of the Year?

Uncharted Waters


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
M. S. Lee, L. Johansen, Y. Zhang, A. Wilson, M. Keegan, W. Avery, P. Elliott, A. A. Borisy, and C. T. Keith
The Novel Combination of Chlorpromazine and Pentamidine Exerts Synergistic Antiproliferative Effects through Dual Mitotic Action
Cancer Res., December 1, 2007; 67(23): 11359 - 11367.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. Vischioni, J. J. Oudejans, W. Vos, J. A. Rodriguez, and G. Giaccone
Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients.
Mol. Cancer Ther., November 1, 2006; 5(11): 2905 - 2913.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Soncini, P. Carpinelli, L. Gianellini, D. Fancelli, P. Vianello, L. Rusconi, P. Storici, P. Zugnoni, E. Pesenti, V. Croci, et al.
PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity.
Clin. Cancer Res., July 1, 2006; 12(13): 4080 - 4089.
[Abstract] [Full Text] [PDF]